Does the media refer more to TNDM or CNXU?

In the previous week, Conexeu Sciences had 8 more articles in the media than Tandem Diabetes Care. MarketBeat recorded 9 mentions for Conexeu Sciences and 1 mentions for Tandem Diabetes Care. Tandem Diabetes Care's average media sentiment score of 0.72 beat Conexeu Sciences' score of 0.07 indicating that Tandem Diabetes Care is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tandem Diabetes Care 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Conexeu Sciences 1 Very Positive mention(s) 0 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to PRCT or CNXU?

In the previous week, Conexeu Sciences had 7 more articles in the media than PROCEPT BioRobotics. MarketBeat recorded 9 mentions for Conexeu Sciences and 2 mentions for PROCEPT BioRobotics. Conexeu Sciences' average media sentiment score of 0.07 beat PROCEPT BioRobotics' score of -0.91 indicating that Conexeu Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PROCEPT BioRobotics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative Conexeu Sciences 1 Very Positive mention(s) 0 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings and valuation, DRTS or CNXU?

Conexeu Sciences is trading at a lower price-to-earnings ratio than Alpha Tau Medical, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alpha Tau Medical N/A N/A -$42.63M -$0.67 N/A Conexeu Sciences N/A N/A N/A -$0.11 N/A

Is DRTS or CNXU more profitable?

Conexeu Sciences' return on equity of 0.00% beat Alpha Tau Medical's return on equity. Company Net Margins Return on Equity Return on Assets Alpha Tau Medical N/A -73.23% -52.90% Conexeu Sciences N/A N/A N/A

Does the media favor DRTS or CNXU?

In the previous week, Alpha Tau Medical and Alpha Tau Medical both had 9 articles in the media. Alpha Tau Medical's average media sentiment score of 0.43 beat Conexeu Sciences' score of 0.07 indicating that Alpha Tau Medical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alpha Tau Medical 2 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Conexeu Sciences 1 Very Positive mention(s) 0 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor INMD or CNXU?

In the previous week, Conexeu Sciences had 7 more articles in the media than InMode. MarketBeat recorded 9 mentions for Conexeu Sciences and 2 mentions for InMode. InMode's average media sentiment score of 0.29 beat Conexeu Sciences' score of 0.07 indicating that InMode is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment InMode 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Conexeu Sciences 1 Very Positive mention(s) 0 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Conexeu Sciences (CNXU) Competitors

$9.15 -0.19 (-2.03%)

Closing price 04:00 PM Eastern

Extended Trading

$9.24 +0.08 (+0.93%)

As of 05:38 PM Eastern

Compare

CNXU vs. TNDM, PRCT, DRTS, BVS, and INMD

Should you buy Conexeu Sciences stock or one of its competitors? MarketBeat compares Conexeu Sciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Conexeu Sciences include Tandem Diabetes Care (TNDM), PROCEPT BioRobotics (PRCT), Alpha Tau Medical (DRTS), Bioventus (BVS), and InMode (INMD). These companies are all part of the "medical equipment" industry.

How does Conexeu Sciences compare to Tandem Diabetes Care?

Tandem Diabetes Care (NASDAQ:TNDM) and Conexeu Sciences (NASDAQ:CNXU) are both small-cap medical equipment companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, profitability, valuation, risk, analyst recommendations, earnings, dividends and institutional ownership.

In the previous week, Conexeu Sciences had 8 more articles in the media than Tandem Diabetes Care. MarketBeat recorded 9 mentions for Conexeu Sciences and 1 mentions for Tandem Diabetes Care. Tandem Diabetes Care's average media sentiment score of 0.72 beat Conexeu Sciences' score of 0.07 indicating that Tandem Diabetes Care is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tandem Diabetes Care	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Conexeu Sciences	1 Very Positive mention(s)	0 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Conexeu Sciences has lower revenue, but higher earnings than Tandem Diabetes Care. Conexeu Sciences is trading at a lower price-to-earnings ratio than Tandem Diabetes Care, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tandem Diabetes Care	$1.01B	1.14	-$204.71M	-$1.40	N/A
Conexeu Sciences	N/A	N/A	N/A	-$0.11	N/A

Conexeu Sciences has a net margin of 0.00% compared to Tandem Diabetes Care's net margin of -9.20%. Conexeu Sciences' return on equity of 0.00% beat Tandem Diabetes Care's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tandem Diabetes Care	-9.20%	-53.88%	-7.88%
Conexeu Sciences	N/A	N/A	N/A

Tandem Diabetes Care currently has a consensus target price of $28.93, suggesting a potential upside of 71.15%. Conexeu Sciences has a consensus target price of $20.00, suggesting a potential upside of 119.54%. Given Conexeu Sciences' stronger consensus rating and higher possible upside, analysts clearly believe Conexeu Sciences is more favorable than Tandem Diabetes Care.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tandem Diabetes Care	1 Sell rating(s)	11 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.45
Conexeu Sciences	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Conexeu Sciences beats Tandem Diabetes Care on 7 of the 12 factors compared between the two stocks.

How does Conexeu Sciences compare to PROCEPT BioRobotics?

PROCEPT BioRobotics (NASDAQ:PRCT) and Conexeu Sciences (NASDAQ:CNXU) are both small-cap medical equipment companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, risk, profitability, institutional ownership and earnings.

Conexeu Sciences has a net margin of 0.00% compared to PROCEPT BioRobotics' net margin of -31.82%. Conexeu Sciences' return on equity of 0.00% beat PROCEPT BioRobotics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PROCEPT BioRobotics	-31.82%	-27.70%	-20.29%
Conexeu Sciences	N/A	N/A	N/A

89.5% of PROCEPT BioRobotics shares are owned by institutional investors. 4.0% of PROCEPT BioRobotics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

PROCEPT BioRobotics currently has a consensus price target of $37.27, indicating a potential upside of 112.38%. Conexeu Sciences has a consensus price target of $20.00, indicating a potential upside of 119.54%. Given Conexeu Sciences' stronger consensus rating and higher possible upside, analysts plainly believe Conexeu Sciences is more favorable than PROCEPT BioRobotics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PROCEPT BioRobotics	2 Sell rating(s)	7 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.33
Conexeu Sciences	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Conexeu Sciences had 7 more articles in the media than PROCEPT BioRobotics. MarketBeat recorded 9 mentions for Conexeu Sciences and 2 mentions for PROCEPT BioRobotics. Conexeu Sciences' average media sentiment score of 0.07 beat PROCEPT BioRobotics' score of -0.91 indicating that Conexeu Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PROCEPT BioRobotics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative
Conexeu Sciences	1 Very Positive mention(s)	0 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Conexeu Sciences has lower revenue, but higher earnings than PROCEPT BioRobotics. Conexeu Sciences is trading at a lower price-to-earnings ratio than PROCEPT BioRobotics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PROCEPT BioRobotics	$308.05M	3.24	-$95.57M	-$1.82	N/A
Conexeu Sciences	N/A	N/A	N/A	-$0.11	N/A

Summary

Conexeu Sciences beats PROCEPT BioRobotics on 8 of the 14 factors compared between the two stocks.

How does Conexeu Sciences compare to Alpha Tau Medical?

Alpha Tau Medical (NASDAQ:DRTS) and Conexeu Sciences (NASDAQ:CNXU) are both small-cap medical equipment companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, risk, institutional ownership, analyst recommendations, dividends, valuation, earnings and profitability.

Conexeu Sciences' return on equity of 0.00% beat Alpha Tau Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alpha Tau Medical	N/A	-73.23%	-52.90%
Conexeu Sciences	N/A	N/A	N/A

Alpha Tau Medical currently has a consensus price target of $12.60, suggesting a potential downside of 5.12%. Conexeu Sciences has a consensus price target of $20.00, suggesting a potential upside of 119.54%. Given Conexeu Sciences' stronger consensus rating and higher possible upside, analysts plainly believe Conexeu Sciences is more favorable than Alpha Tau Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alpha Tau Medical	2 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.38
Conexeu Sciences	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Alpha Tau Medical and Alpha Tau Medical both had 9 articles in the media. Alpha Tau Medical's average media sentiment score of 0.43 beat Conexeu Sciences' score of 0.07 indicating that Alpha Tau Medical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alpha Tau Medical	2 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Conexeu Sciences	1 Very Positive mention(s)	0 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

2.7% of Alpha Tau Medical shares are held by institutional investors. 39.5% of Alpha Tau Medical shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Conexeu Sciences is trading at a lower price-to-earnings ratio than Alpha Tau Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alpha Tau Medical	N/A	N/A	-$42.63M	-$0.67	N/A
Conexeu Sciences	N/A	N/A	N/A	-$0.11	N/A

Summary

Alpha Tau Medical and Conexeu Sciences tied by winning 5 of the 10 factors compared between the two stocks.

How does Conexeu Sciences compare to Bioventus?

Conexeu Sciences (NASDAQ:CNXU) and Bioventus (NASDAQ:BVS) are both small-cap manufacturing companies, but which is the better business? We will compare the two companies based on the strength of their dividends, valuation, earnings, analyst recommendations, media sentiment, profitability, institutional ownership and risk.

In the previous week, Conexeu Sciences had 9 more articles in the media than Bioventus. MarketBeat recorded 9 mentions for Conexeu Sciences and 0 mentions for Bioventus. Bioventus' average media sentiment score of 1.06 beat Conexeu Sciences' score of 0.07 indicating that Bioventus is being referred to more favorably in the news media.

Company	Overall Sentiment
Conexeu Sciences	Neutral
Bioventus	Positive

Bioventus has a net margin of 4.94% compared to Conexeu Sciences' net margin of 0.00%. Bioventus' return on equity of 29.97% beat Conexeu Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Conexeu Sciences	N/A	N/A	N/A
Bioventus	4.94%	29.97%	9.52%

62.9% of Bioventus shares are held by institutional investors. 33.5% of Bioventus shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Conexeu Sciences currently has a consensus target price of $20.00, indicating a potential upside of 119.54%. Bioventus has a consensus target price of $14.75, indicating a potential upside of 28.48%. Given Conexeu Sciences' higher probable upside, analysts plainly believe Conexeu Sciences is more favorable than Bioventus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Conexeu Sciences	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
Bioventus	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	3.00

Bioventus has higher revenue and earnings than Conexeu Sciences. Conexeu Sciences is trading at a lower price-to-earnings ratio than Bioventus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Conexeu Sciences	N/A	N/A	N/A	-$0.11	N/A
Bioventus	$568.09M	1.69	$22.73M	$0.41	28.00

Summary

Bioventus beats Conexeu Sciences on 12 of the 14 factors compared between the two stocks.

How does Conexeu Sciences compare to InMode?

InMode (NASDAQ:INMD) and Conexeu Sciences (NASDAQ:CNXU) are both small-cap medical equipment companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, profitability, valuation, institutional ownership, dividends, risk and earnings.

InMode currently has a consensus target price of $16.00, suggesting a potential upside of 6.03%. Conexeu Sciences has a consensus target price of $20.00, suggesting a potential upside of 119.54%. Given Conexeu Sciences' stronger consensus rating and higher probable upside, analysts clearly believe Conexeu Sciences is more favorable than InMode.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InMode	1 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Conexeu Sciences	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

InMode has higher revenue and earnings than Conexeu Sciences. Conexeu Sciences is trading at a lower price-to-earnings ratio than InMode, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InMode	$370.49M	2.34	$93.83M	$1.36	11.10
Conexeu Sciences	N/A	N/A	N/A	-$0.11	N/A

In the previous week, Conexeu Sciences had 7 more articles in the media than InMode. MarketBeat recorded 9 mentions for Conexeu Sciences and 2 mentions for InMode. InMode's average media sentiment score of 0.29 beat Conexeu Sciences' score of 0.07 indicating that InMode is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
InMode	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Conexeu Sciences	1 Very Positive mention(s)	0 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

68.0% of InMode shares are owned by institutional investors. 6.9% of InMode shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

InMode has a net margin of 23.27% compared to Conexeu Sciences' net margin of 0.00%. InMode's return on equity of 13.47% beat Conexeu Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InMode	23.27%	13.47%	11.95%
Conexeu Sciences	N/A	N/A	N/A

Summary

InMode beats Conexeu Sciences on 9 of the 12 factors compared between the two stocks.

Get Conexeu Sciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CNXU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CNXU vs. The Competition

Export

Metric	Conexeu Sciences	Surgical, Medical, And Dental Instruments And Supplies Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$243.77M	$3.02B	$7.54B	$12.29B
Dividend Yield	N/A	N/A	38.38%	9.41%
P/E Ratio	-82.82	20.80	23.67	23.86
Price / Sales	N/A	246.18	135.02	114.80
Price / Cash	N/A	8.89	165.13	60.45
Price / Book	N/A	5.38	12.81	6.10
Net Income	N/A	$23.43M	$120.21M	$331.84M
7 Day Performance	-13.32%	-4.42%	-0.60%	-1.76%
1 Month Performance	-13.65%	-8.38%	-2.02%	-3.03%
1 Year Performance	N/A	0.89%	9.35%	14.19%

Conexeu Sciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CNXU Conexeu Sciences	2.9932 of 5 stars	$9.15 -2.0%	$20.00 +118.6%	N/A	$244.84M	N/A	N/A	4	News Coverage
TNDM Tandem Diabetes Care	2.3496 of 5 stars	$17.08 +4.8%	$28.93 +69.4%	+10.5%	$1.12B	$1.01B	N/A	2,500
PRCT PROCEPT BioRobotics	2.543 of 5 stars	$19.22 +0.1%	$37.27 +93.9%	-69.9%	$1.09B	$308.05M	N/A	430	News Coverage
DRTS Alpha Tau Medical	1.741 of 5 stars	$13.55 +14.1%	$12.60 -7.0%	+326.6%	$1.07B	N/A	N/A	80	Analyst Forecast Gap Down
BVS Bioventus	4.2717 of 5 stars	$12.06 -3.0%	$14.75 +22.3%	+80.6%	$1.04B	$576.30M	29.41	1,200	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CNXU) was last updated on 7/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Conexeu Sciences (CNXU) Competitors

CNXU vs. TNDM, PRCT, DRTS, BVS, and INMD

How does Conexeu Sciences compare to Tandem Diabetes Care?

Summary

How does Conexeu Sciences compare to PROCEPT BioRobotics?

Summary

How does Conexeu Sciences compare to Alpha Tau Medical?

Summary

How does Conexeu Sciences compare to Bioventus?

Summary

How does Conexeu Sciences compare to InMode?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CNXU vs. The Competition

Conexeu Sciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Conexeu Sciences (CNXU) Competitors

CNXU vs. TNDM, PRCT, DRTS, BVS, and INMD

How does Conexeu Sciences compare to Tandem Diabetes Care?

Does the media refer more to TNDM or CNXU?

Which has preferable earnings & valuation, TNDM or CNXU?

Is TNDM or CNXU more profitable?

Do analysts recommend TNDM or CNXU?

Summary

How does Conexeu Sciences compare to PROCEPT BioRobotics?

Is PRCT or CNXU more profitable?

Do institutionals & insiders hold more shares of PRCT or CNXU?

Do analysts rate PRCT or CNXU?

Does the media refer more to PRCT or CNXU?

Which has better earnings and valuation, PRCT or CNXU?

Summary

How does Conexeu Sciences compare to Alpha Tau Medical?

Is DRTS or CNXU more profitable?

Do analysts recommend DRTS or CNXU?

Does the media favor DRTS or CNXU?

Do institutionals and insiders believe in DRTS or CNXU?

Which has preferable earnings and valuation, DRTS or CNXU?

Summary

How does Conexeu Sciences compare to Bioventus?

Does the media favor CNXU or BVS?

Is CNXU or BVS more profitable?

Do institutionals & insiders have more ownership in CNXU or BVS?

Do analysts prefer CNXU or BVS?

Which has preferable valuation & earnings, CNXU or BVS?

Summary

How does Conexeu Sciences compare to InMode?

Do analysts recommend INMD or CNXU?

Which has stronger valuation and earnings, INMD or CNXU?

Does the media favor INMD or CNXU?

Do institutionals & insiders hold more shares of INMD or CNXU?

Is INMD or CNXU more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CNXU vs. The Competition

Conexeu Sciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools